Transgene

OverviewSuggest Edit

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S.
TypePublic
HQIllkirch, FRMap
Websitetransgene.fr
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2020)139(+3%)
Share Price (Jan 2021)€2 (-3%)
Cybersecurity ratingAMore

Key People/Management at Transgene

Juan Pedro R. Serrate

Juan Pedro R. Serrate

Analyst

Transgene Office Locations

Transgene has offices in Illkirch, Lyon, Boston and Shanghai
Shanghai, CN
Rm 508, Building 2 4633, Pusan Road Kangqiao Industrial Park, Pudong Shanghai
Lyon, FR
321 Avenue Jean Jaurès
Boston, MA, US
201 Washington St
Show all (4)

Transgene Financials and Metrics

Transgene Revenue

Market capitalization (15-Jan-2021)

170.6m

Closing stock price (15-Jan-2021)

2.0
Transgene's current market capitalization is €170.6 m.
Show all financial metrics

Transgene Cybersecurity Score

Cybersecurity ratingPremium dataset

A

99/100

Learn more about our premium products
SecurityScorecard logo

Transgene Online and Social Media Presence

Transgene's Trends

Embed Graph

Transgene News and Updates

December 21, 2020

BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors

LUND, Sweden and STRASBOURG, France, Dec. 21, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext...
October 15, 2020

BioInvent and Transgene to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

LUND, Sweden and STRASBOURG, France, Oct. 15, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext...
December 11, 2019

BioInvent and Transgene Announce Compelling Preclinical Data for BT-001 in Solid Tumors

LUND, Sweden and STRASBOURG, France, Dec. 11, 2019 /PRNewswire/ -- BioInvent International AB (publ) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris:...
November 06, 2019

CTIBiotech - Transgene Collaboration for Cancer Research

CTIBioTumour: Human Tumours Produced by 3D Bioprinting to Accelerate the Development of New Cancer Therapies
May 02, 2019

AstraZeneca ties up with France's Transgene to develop viral immunotherapies

British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.
March 26, 2019

BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors

LUND, Sweden and STRASBOURG, France, March 26, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV), a biotech company focused on the discovery and development of novel immuno-regulatory antibodies to treat cancer and Transgene (Euronext Paris: TNG), a biotech company that designs ...
Show more

Transgene Blogs

November 26, 2020

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators

Franck Gallardo, et al. Biomedicines, November 26 2020 - Read the article Publication
November 09, 2020

BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment

Poster BT-001 M. Semmrich et al. SITC 2020 Download the abstract here Poster Presentation
November 09, 2020

TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity

Poster SITC TG4001 C. Le Tourneau et al. SITC 2020 Download the poster here Poster Presentation
July 08, 2020

Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine

Poster EUROoCS H. Le et al. EUROoCS 2020 Download the poster here Poster Presentation
June 22, 2020

Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects

AACR2020 6010 J. Foloppe et al. AACR 2020 Download the poster here Poster Presentation
June 22, 2020

Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine

AACR2020 myvac B. Mallone et al. AACR 2020 Download the poster here Poster Presentation
Show more

 Transgene Frequently Asked Questions

  • Who are Transgene key executives?

    Transgene's key executives are Juan Pedro R. Serrate.

  • How many employees does Transgene have?

    Transgene has 139 employees.

  • Who are Transgene competitors?

    Competitors of Transgene include EpiVax, Magenta Therapeutics and Synthace.

  • Where are Transgene offices?

    Transgene has offices in Illkirch, Lyon, Boston and Shanghai.

  • How many offices does Transgene have?

    Transgene has 4 offices.